Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure.
The embryo viability product is being developed by Novocellus, which is 82% owned by Angle.
The firm had already said the trial of EmbryoSure was delayed, but today added that the timeframe for completing the trials was "at present uncertain".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Agnle would meet with Origio, the firm responisble for the trials, at the end of this month to review options for progressing the trials, it said.
"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible," said chief executive Andrew Newland.
Angle's share price fell 6% after the announcement.
-
Going part-time could leave a £58,000 hole in your pension: how to plug the gapThere are many reasons for switching to part-time work, but some savers don’t consider the impact on their pension until it is too late
-
Three bargain investment trusts to add to your portfolioThese three investment trusts are bargains compared to their net asset value (NAV), but one fund analyst thinks the deep discounts are unwarranted.
